Pathophysiology of atopic dermatitis and psoriasis: Implications for management in children

Raj Chovatiya; Jonathan I. Silverberg

doi:10.3390/children6100108

Pathophysiology of atopic dermatitis and psoriasis: Implications for management in children

Raj Chovatiya, Jonathan I. Silverberg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

Original language	English (US)
Article number	108
Journal	Children
Volume	6
Issue number	10
DOIs	https://doi.org/10.3390/children6100108
State	Published - Oct 2019

Keywords

Atopic dermatitis
Biologic therapy
Cytokine
Inflammation
Psoriasis
Skin-barrier
Systemic therapy
Topical therapy

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.3390/children6100108

Cite this

@article{6d414352ca3a46a19fdd212e90893e3f,

title = "Pathophysiology of atopic dermatitis and psoriasis: Implications for management in children",

abstract = "Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.",

keywords = "Atopic dermatitis, Biologic therapy, Cytokine, Inflammation, Psoriasis, Skin-barrier, Systemic therapy, Topical therapy",

author = "Raj Chovatiya and Silverberg, {Jonathan I.}",

note = "Funding Information: Conflicts of Interest: Jonathan Silverberg reports personal fees from Abbvie, Anaptysbio, Asana, EliLilly, Galderma, GlaxoSmithKline, Kiniksa, Leo, Menlo, Pfizer, Realm, RegeneronSanofi, and Roivant, and grants from GlaxoSmithKline, RegeneronSanofi, and Galderma, during the conduct of the Review. Raj Chovatiya declares no competing interests. Funding Information: Funding: This research received no external funding. Jonathan I. Silverberg is supported by a grant from the Dermatology Foundation. Raj Chovatiya is supported by a grant from the National Institutes of Health T32AR060710. The funding source had no involvement in design of the review or in curation, analysis, preparation, review, editing, or approval of the manuscript. Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = oct,

doi = "10.3390/children6100108",

language = "English (US)",

volume = "6",

journal = "Children",

issn = "2227-9067",

publisher = "MDPI AG",

number = "10",

}

TY - JOUR

T1 - Pathophysiology of atopic dermatitis and psoriasis

T2 - Implications for management in children

AU - Chovatiya, Raj

AU - Silverberg, Jonathan I.

N1 - Funding Information: Conflicts of Interest: Jonathan Silverberg reports personal fees from Abbvie, Anaptysbio, Asana, EliLilly, Galderma, GlaxoSmithKline, Kiniksa, Leo, Menlo, Pfizer, Realm, RegeneronSanofi, and Roivant, and grants from GlaxoSmithKline, RegeneronSanofi, and Galderma, during the conduct of the Review. Raj Chovatiya declares no competing interests. Funding Information: Funding: This research received no external funding. Jonathan I. Silverberg is supported by a grant from the Dermatology Foundation. Raj Chovatiya is supported by a grant from the National Institutes of Health T32AR060710. The funding source had no involvement in design of the review or in curation, analysis, preparation, review, editing, or approval of the manuscript. Publisher Copyright: © 2019 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2019/10

Y1 - 2019/10

N2 - Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

AB - Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

KW - Atopic dermatitis

KW - Biologic therapy

KW - Cytokine

KW - Inflammation

KW - Psoriasis

KW - Skin-barrier

KW - Systemic therapy

KW - Topical therapy

UR - http://www.scopus.com/inward/record.url?scp=85080019042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080019042&partnerID=8YFLogxK

U2 - 10.3390/children6100108

DO - 10.3390/children6100108

M3 - Article

C2 - 31590274

AN - SCOPUS:85080019042

SN - 2227-9067

VL - 6

JO - Children

JF - Children

IS - 10

M1 - 108

ER -

Pathophysiology of atopic dermatitis and psoriasis: Implications for management in children

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this